Watson's Famvir ANDA Suffers "Compound" Fracture, Downgraded To Tentative
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's revises the approval status of the generic version of the herpes treatment two days after Novartis sues the agency says that Watson failed to certify compound claims in the Famvir patent.